Refilling and switching of antiepileptic drugs and seizure-related events

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 347-353

  Gagne, J J ^a   Avorn, J ^a   Shrank, W H ^a   Schneeweiss, S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SEIZURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTICONVULSANTS; BRITISH COLUMBIA; CASE-CONTROL STUDIES; CHILD; CROSS-OVER STUDIES; DATABASES, FACTUAL; DRUGS, GENERIC; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISK; SEIZURES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955926153     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.90     Document Type: Article

References (48)

1. Health Canada. Guidance for Industry: Conduct and Analysis of Bioavailability and Bioequivalence studies: part A: Oral Dosage Formulations Used for systemic Efects (1997). Accessed 10 October 2009.
2. Us Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence studies for Orally Administered Drug products\General Considerations (2003). Accessed 20 May 2008.
3. European Medicines Agency. Guideline on the Investigation of Bioequivalence (2008). Accessed 10 October 2009.
4. Andermann, F., Duh, M.S., Gosselin, A. & Paradis, P.E. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48, 464-469 (2007).
5. Berg, M.J. What's the problem with generic antiepileptic drugs?: a call to action. Neurology 68, 1245-1246 (2007).
6. Liow, K., Barkley, G.L., Pollard, J.R., Harden, C.L. & Bazil, C.W.; American Academy of Neurology. position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 68, 1249-1250 (2007).
7. Berg, M.J., Gross, R.A., Haskins, L.S., Zingaro, W.M. & Tomaszewski, K.J. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav. 13, 693-699 (2008).
8. Papsdorf, T.B., Ablah, E., Ram, S., Sadler, T. & Liow, K. Patient perception of generic antiepileptic drugs in the Midwestern United states. Epilepsy Behav. 14, 150-153 (2009).
9. McAuley, J.W., Chen, A.Y., Elliott, J.O. & Shneker, B.F. An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy. Epilepsy Behav. 14, 113-117 (2009).
10. Urquhart, J. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. Br. J. Clin. Pharmacol. 54, 212-220 (2002).
11. MacDonald, J.T. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 37, 1885 (1987).
12. Besag, F.M. Is generic prescribing acceptable in epilepsy? Drug Saf. 23, 173-182 (2000).
13. Zachry, W.M. 3rd, Doan, Q.D., Clewell, J.D. & Smith, B.J. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 50, 493-500 (2009).
14. Rascati, K.L., Richards, K.M., Johnsrud, M.T. & Mann, T.A. Efects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy 29, 769-774 (2009).
15. Hansen, R.N., Campbell, J.D. & Sullivan, S.D. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav. 15, 481-485 (2009).
16. Devine, S.T., Weisbart, E., Barron, J. & Behm, A. Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs. Curr. Med. Res. Opin. 26, 455-463 (2010).
17. Kesselheim, A.S. et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 70, 605-621 (2010).
18. Schneeweiss, S., Stürmer, T. & Maclure, M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol. Drug Saf. 6 (suppl. 3), s51-s59 (1997).
19. Manjunath, R., Davis, K.L., Candrilli, S.D. & Ettinger, A.B. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav. 14, 372-378 (2009).
20. Cramer, J.A., Glassman, M. & Rienzi, V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 3, 338-342 (2002).
21. Shrank, W.H. et al. The variability and quality of medication container labels. Arch. Intern. Med. 167, 1760-1765 (2007).
22. Harter, J.G. & Peck, C.C. Chronobiology. suggestions for integrating it into drug development. Ann. NY Acad. Sci. 618, 563-571 (1991).
23. Burnier, M., Schneider, M.P., Chioléro, A., Stubi, C.L. & Brunner, H.R. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J. Hypertens. 19, 335-341 (2001).
24. Davit, B.M. et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United states Food and Drug Administration. Ann. Pharmacother. 43, 1583-1597 (2009).
25. Perucca, E., Albani, F., Capovilla, G., Bernardina, B.D., Michelucci, R. & Zaccara, G. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 47 (suppl. 5), 16-20 (2006).
26. Bialer, M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 48, 1825-1832 (2007).
27. Boylan, L.S. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 72, 1876; author reply 1876-1876; author reply 1877 (2009).
28. Meyer, M.C. et al. Variability in the bioavailability of phenytoin capsules in males and females. Pharm. Res. 18, 394-397 (2001).
29. Measurement error. In Methods in Observational Epidemiology 2nd edn. (eds. Kelsey, J.L., Whittemore, A.S., Evans, A.S. & Thompson, W.D.) 341-363 (Oxford University press, New York, 1996).
30. Liow, K. Understanding patients' perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication. BMC Neurol. 9, 11 (2009).
31. Williams, R.L. Therapeutic equivalence of generic drugs: response to the National Association of Boards of pharmacy (letter) (16 April 1997)
32. Epilepsy Foundation. statement on generic substitution of AEDshttp://www.epilepsyfoundation.org/advocacy/care/genedrev.cfm>. Accessed 12 October 2009.
33. National Black Caucus of state Legislators. Resolution HHs-07-19. Epilepsy patient prescription drug safety. Accessed 12 October 2009
34. Hawaii revised statutes. Accessed 12 October 2009.
35. Maclure, M. The case-crossover design: a method for studying transient efects on the risk of acute events. Am. J. Epidemiol. 133, 144-153 (1991).
36. Schneeweiss, S. Developments in post-marketing comparative efectiveness research. Clin. Pharmacol. Ther. 82, 143-156 (2007).
37. Schneeweiss, S. & Avorn, J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J. Clin. Epidemiol. 58, 323-337 (2005).
38. Di Bonaventura, C., Fattouch, J., Fabbrini, G., Manfredi, M., Prencipe, M. & Giallonardo, T.A. switching from branded to generic antiepileptic drugs as a confounding factor and unpredictable diagnostic pitfall in epilepsy management. Epileptic Disord. 9, 465-466 (2007).
39. Crawford, P., Feely, M., Guberman, A. & Kramer, G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 15, 165-176 (2006).
40. Mittleman, M.A., Maclure, M. & Robins, J.M. Control sampling strategies for case-crossover studies: an assessment of relative efciency. Am. J. Epidemiol. 142, 91-98 (1995).
41. Schelleman, H., Bilker, W.B., Brensinger, C.M., Han, X., Kimmel, S.E. & Hennessy, S. Warfarin with fuoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin. Pharmacol. Ther. 84, 581-588 (2008).
42. Robins, J.M., Hernán, M.A. & Brumback, B. Marginal structural models and causal inference in epidemiology. Epidemiology 11, 550-560 (2000).
43. Abadie, A. Semiparametric diference-in-diferences estimators. Rev. Econ. Stud. 72, 1-19 (2005).
44. Schneeweiss, S., Maclure, M., Soumerai, S.B., Walker, A.M. & Glynn, R.J. Quasi-experimental longitudinal designs to evaluate drug beneft policy changes with low policy compliance. J. Clin. Epidemiol. 55, 833-841 (2002).
45. Suissa, S. The case-time-control design. Epidemiology 6, 248-253 (1995).
46. Suissa, S. The case-time-control design: further assumptions and conditions. Epidemiology 9, 441-445 (1998).
47. Greenland, S. Confounding and exposure trends in case-crossover and case-time-control designs. Epidemiology 7, 231-239 (1996).
48. Davis, K.L., Candrilli, S.D. & Edin, H.M. prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 49, 446-454 (2008).